

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10727580
Filing Date	2003-12-05
First Named Inventor	SAUVAGEAU, Guy
Art Unit	1636
Examiner Name	DUNSTON Jennifer Ann
Attorney Docket Number	765/12810.186

Sheet 1 of 2

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	1	YANG et al., "HIV-1 TAT-mediated protein transduction and subcellular localization using novel expression vectors", FEBS Letters, 532 (2002):26-44	
	2	REIS et al., "Prospects of TAT-mediated protein therapy for fragile X syndrome", J Mol Histol. 2004 May, 35(4):389-35, Abstract only	
	3	EL-ANDALOUSSI et al., "Cargo-dependent cytotoxicity and delivery efficacy of cell--penetrating peptides: a comparative study", Biochem J. (2007), 407:285-292	
	4	JONES et al., "Characterisation of cell-penetrating peptide-mediated peptide delivery", British Journal of Pharmacology (2005), 145:1093-1102	
	5	SPITERE et al., "TAX-PAX6 protein transduction in neural progenitor cells: a novel approach for generation of dopaminergic neurones in vitro", Brain Res. 2008 May 7, 1208:25-3 Abstract only	
	6	FALNES et al., "Ability of the Tat basic domain and VP22 to mediate cell binding, but not membrane translocation of the diphtheria toxin A-fragment", Biochemistry, 2001 Apr 10 40(14): 4349-4558, Abstract only	
	7	NAGEL et al., "Quantitative evaluation of chaperone activity and neuroprotection by different preparations of a cell-penetrating Hsp70", J Neurosci Methods, 2008 Jun 30, 171(2)	
	8	SCHOEMANS et al., "Adult umbilical cord blood transplantation: a comprehensive review", Bone Marrow Transplantation (2006) 38:83-93	
	9	ZHANG et al., "High incidence of leukemia in large animals after stem cell gene therapy with a HOXB4-expressing retroviral vector", J. Clinical Investigation, April 2008, 118 1502-1510	
	10	PINEAULT et al., "Differential and Common Leukemogenic Potentials of Multiple NUP98-Hox Fusion Proteins Alone or with Meis1", Mol and Cell Biology, Mar. 2004, p. 1907-1917	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO:**

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /JD/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10727580
				Filing Date	2003-12-05
				First Named Inventor	SAUVAGEAU, Guy
				Art Unit	1636
				Examiner Name	DUNSTON Jennifer Ann
Sheet	2	of	2	Attorney Docket Number	765/12810.186

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	11	BAUM et al., "Side effects of retroviral gene transfer into hematopoietic stem cells", Blood, 15 march 2003, 101(6):2099-2114	
	12	BAUM, Christopher, "Insertional mutagenesis in gene therapy and stem cell biology", Current Opinion in Hematology, July 2007, 14(4):337-342, Abstract only	

Examiner Signature	/Jennifer Dunston/ (03/25/2009)	Date Considered	
--------------------	---------------------------------	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /JD/